Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Bladder Cancer
  • Melanoma
  • Non -Small Cell Lung Cancer
  • Pancreatic Cancer
  • Solid Tumor, Adult
  • Triple -Negative Breast Cancer
  • Virus-associated Tumors
Type
Interventional
Phase
Phase 2
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: 6 independent single-arm, multicenter, phase II trials, based on 2-stage Simon's optimal design (Simon R, Controlled Clinical Trials 1989): Population 1: pancreatic cancer Population 2: virus-associated tumors Population 3: non-small lung cancer Population 4: soft-tissue sarcoma Population 5: bladder cancer Population 6: triple negative breast cancer Masking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

6 independent, multicenter, prospective, single-arm phase II trials, based on 2-stage Simon's optimal design, will be conducted in parallel to assess the efficacy of atezolimab + BDB001+ radiotherapy, separately, in distinct populations of solid tumors: Population 1: pancreatic cancer Population 2: ...

6 independent, multicenter, prospective, single-arm phase II trials, based on 2-stage Simon's optimal design, will be conducted in parallel to assess the efficacy of atezolimab + BDB001+ radiotherapy, separately, in distinct populations of solid tumors: Population 1: pancreatic cancer Population 2: virus-associated tumors Population 3: anti-PD-1/L1 refractory non-small lung cancer Population 4: soft-tissue sarcoma Population 5: anti-PD-1/L1 refractory bladder cancer Population 6: anti-PD-1/L1 refractory triple negative breast cancer

Tracking Information

NCT #
NCT03915678
Collaborators
  • Roche Pharma AG
  • National Cancer Institute, France
  • Seven and Eight Biopharmaceuticals Inc
Investigators
Not Provided
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024